The effects of Xingnaojing injection on cytokine and clinical efficacy of patients with acute cerebral infarction and blood stasis syndrome / 中国中西医结合急救杂志

ABSTRACT

Objective To observe the effects of Xingnaojing injection on cytokine and clinical efficacy of patients with acute cerebral infarction (ACI) and blood stasis syndrome (BSS).Methods A prospective randomized controlled trial was conducted. Seventy hospitalized patients with ACI in the Neurological Department of the First People's Hospital of Jingmen of Hubei Province were enrolled, and they were randomly divided into a combination of traditional Chinese and western medicine group and a control group, 35 cases in each group. Both groups received conventional treatment. The combination therapy group additionally received Xingnaojing intravenous drip 30 mL, once a day on the basis of the control remedy. The therapeutic course in both groups was 14 days. In the two groups before and after treatment, the serum levels of γ-interferon (IFN-γ) and interleukins (IL-2, IL-5 and IL-10) were detected; the neurological function defect scale (NFDS) score, the modified Rankin scale (MRS) score and the daily living activity (ADL) score were observed.Results Compared with the levels before treatment, serum levels of IFN-γ and IL-2 were significantly decreased after treatment [IFN-γ (ng/L) the control group was 32.62±5.34 vs. 45.89±9.28, combination therapy group was 20.45±6.39 vs. 46.02±8.15; IL-2 (ng/L) the control group was 8.62±1.51 vs. 14.23±2.19, combination therapy group was 3.47±0.76 vs. 13.09±1.32], while the levels of IL-5 and IL-10 were obviously increased [IL-5 (ng/L) the control group was 68.39±8.89 vs. 36.80±6.32, combination therapy group was 89.20±9.17 vs. 37.26±6.08; IL-10 (ng/L) the control group was 27.66±5.47 vs. 15.59±3.27, combination therapy group was 38.54±7.66 vs. 16.17±4.29], and the changes in the combination therapy group were more significant [IFN-γ (ng/L)20.45±6.39 vs. 32.62±5.34, IL-2 (ng/L) 3.47±0.76 vs. 8.62±1.51, IL-5 (ng/L) 89.20±9.17 vs. 68.39±8.89, IL-10 (ng/L) 38.54±7.66 vs. 27.66±5.47, allP < 0.05]. Compared with the scores before treatment, NFDS score and MRS score were significantly decreased after treatment (NFDS score the control group was 12.38±4.26 vs. 27.16±6.35, the combination therapy group was 7.59±2.09 vs. 28.53±7.57; MRS score the control group was 3.39±1.51 vs. 4.58±1.07, the combination therapy group was 1.39±0.76 vs. 4.65±1.12), but the ADL score was significantly increased after treatment (the control group was 38.17±2.24 vs. 24.25±3.53, the combination therapy group was 48.43±1.32 vs. 23.51±2.17), and the improvement in the combination therapy group was more significant (NFDS score 7.59±2.09 vs. 12.38±4.26, MRS score 1.39±0.76 vs. 3.39±1.51, ADL score 48.43±1.32 vs. 38.17±2.24, allP < 0.05).Conclusion The Xingnaojing injection can significantly regulate the levels of serum cytokines IFN-γ, IL-2, IL-5, IL-10, and improve the recovery of function of damaged nerve and the ADL in patients with ACI.